A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
Completed · Phase 1 · NCT05894928
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $55,089
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 21
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- LOXO-783 (drug), Cholestyramine (drug)
- Dates
- Started 2023-06-07; completion 2023-07-09
- Results posted
- Not yet
The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.
From ClinicalTrials.gov, last updated 2023-09-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $55,089 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hugh A. Coleman, DO Family Medicine · Daytona Beach, FL
- Adeyemi T. Gbohunmi, M.D., PH.D. General Practice · Fort Worth, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $27,544
- Covance Clinical Research LP Dallas $27,544
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.